Skip to content
2000
Volume 33, Issue 3
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Large-scale infectious diseases have become a significant threat to human health and safety. The successful invention of vaccines is the most powerful means for preventing infectious diseases and has greatly improved global human health. Even during the pandemic of COVID-19, which has affected the world, vaccines have played an irreplaceable role. Microneedles (MNs) punctured the stratum corneum and formed microchannels in the skin allowing the vaccine to be efficiently recognized by the abundant antigen-presenting cells (APCs) in the skin to form specific immunity. Compared with traditional vaccination methods, MN transdermal immunization has the advantages of painlessness, easy storage, and efficient immune response. In this review, we summarize the types of vaccines, types of MNs, research progress and clinical research status of MN-based vaccines. We also cover various technologies for vaccine encapsulation, stable delivery of MN vaccines, and a wide range of potential clinical applications. We also outline the future development prospects of the MN system onboard to achieve better clinical benefits.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673336874241129081141
2025-01-24
2026-02-23

  • From This Site

    /content/journals/cmc/10.2174/0109298673336874241129081141
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmc/33/3/CMC-33-3-02.html?itemId=/content/journals/cmc/10.2174/0109298673336874241129081141&mimeType=html&fmt=ahah

References

  1. MaG. WuC. Microneedle, bio-microneedle and bio-inspired microneedle: A review.J. Control. Release2017251112310.1016/j.jconrel.2017.02.01128215667
     [Google Scholar]
  2. YuJ. WangJ. ZhangY. ChenG. MaoW. YeY. KahkoskaA.R. BuseJ.B. LangerR. GuZ. Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs.Nat. Biomed. Eng.20204549950610.1038/s41551‑019‑0508‑y32015407
     [Google Scholar]
  3. BalmertS.C. CareyC.D. FaloG.D. SethiS.K. ErdosG. KorkmazE. FaloL.D. Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination.J. Control. Release202031733634610.1016/j.jconrel.2019.11.02331756393
     [Google Scholar]
  4. IapichinoM. MaibachH. StoeberB. Quantification methods comparing in vitro and in vivo percutaneous permeation by microneedles and passive diffusion.Int. J. Pharm.202363812288510.1016/j.ijpharm.2023.12288537015294
     [Google Scholar]
  5. SullivanS.P. KoutsonanosD.G. del Pilar MartinM. LeeJ.W. ZarnitsynV. ChoiS.O. MurthyN. CompansR.W. SkountzouI. PrausnitzM.R. Dissolving polymer microneedle patches for influenza vaccination.Nat. Med.201016891592010.1038/nm.218220639891
     [Google Scholar]
  6. HirobeS. AzukizawaH. HanafusaT. MatsuoK. QuanY.S. KamiyamaF. KatayamaI. OkadaN. NakagawaS. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch.Biomaterials201557505810.1016/j.biomaterials.2015.04.00725913250
     [Google Scholar]
  7. MercerA. Protection against severe infectious disease in the past.Pathog. Glob. Health2021115315116710.1080/20477724.2021.187844333573529
     [Google Scholar]
  8. DonnellyR.F. Vaccine delivery systems.Hum. Vaccin. Immunother.2017131171810.1080/21645515.2016.125904328125375
     [Google Scholar]
  9. HegdeN.R. KaveriS.V. BayryJ. Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination.Drug Discov. Today20111623-241061106810.1016/j.drudis.2011.07.00421782969
     [Google Scholar]
  10. StoitznerP. SparberF. TrippC.H. Langerhans cells as targets for immunotherapy against skin cancer.Immunol. Cell Biol.201088443143710.1038/icb.2010.3120351746
     [Google Scholar]
  11. PrausnitzM.R. Microneedles for transdermal drug delivery.Adv. Drug Deliv. Rev.200456558158710.1016/j.addr.2003.10.02315019747
     [Google Scholar]
  12. KenneyR.T. YuJ. Guebre-XabierM. FrechS.A. LambertA. HellerB.A. EllingsworthL.R. EylesJ.E. WilliamsonE.D. GlennG.M. Induction of protective immunity against lethal anthrax challenge with a patch.J. Infect. Dis.2004190477478210.1086/42269415272406
     [Google Scholar]
  13. MinorP.D. Live attenuated vaccines: Historical successes and current challenges.Virology2015479-48037939210.1016/j.virol.2015.03.03225864107
     [Google Scholar]
  14. LauringA.S. JonesJ.O. AndinoR. Rationalizing the development of live attenuated virus vaccines.Nat. Biotechnol.201028657357910.1038/nbt.163520531338
     [Google Scholar]
  15. KewO.M. SutterR.W. de GourvilleE.M. DowdleW.R. PallanschM.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication.Annu. Rev. Microbiol.200559158763510.1146/annurev.micro.58.030603.12362516153180
     [Google Scholar]
  16. FrancisM.J. Recent advances in vaccine technologies.Vet. Clin. North Am. Small Anim. Pract.201848223124110.1016/j.cvsm.2017.10.00229217317
     [Google Scholar]
  17. KumruO.S. JoshiS.B. SmithD.E. MiddaughC.R. PrusikT. VolkinD.B. Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies.Biologicals201442523725910.1016/j.biologicals.2014.05.00724996452
     [Google Scholar]
  18. D’AmicoC. FontanaF. ChengR. SantosH.A. Development of vaccine formulations: past, present, and future.Drug Deliv. Transl. Res.202111235337210.1007/s13346‑021‑00924‑733598818
     [Google Scholar]
  19. VetterV. DenizerG. FriedlandL.R. KrishnanJ. ShapiroM. Understanding modern-day vaccines: what you need to know.Ann. Med.201850211012010.1080/07853890.2017.140703529172780
     [Google Scholar]
  20. JegaskandaS. CoM.D.T. CruzJ. SubbaraoK. EnnisF.A. TerajimaM. Induction of H7N9-cross-reactive antibody-dependent cellular cytotoxicity antibodies by human seasonal influenza a viruses that are directed toward the nucleoprotein.J. Infect. Dis.2017215581882328011910
     [Google Scholar]
  21. JegaskandaS. LukeC. HickmanH.D. SangsterM.Y. Wieland-AlterW.F. McBrideJ.M. YewdellJ.W. WrightP.F. TreanorJ. RosenbergerC.M. SubbaraoK. Generation and protective ability of influenza virus–specific antibody-dependent cellular cytotoxicity in Humans elicited by vaccination, natural infection, and experimental challenge.J. Infect. Dis.2016214694595210.1093/infdis/jiw26227354365
     [Google Scholar]
  22. SchotsaertM. García-SastreA. Inactivated influenza virus vaccines: the future of TIV and QIV.Curr. Opin. Virol.20172310210610.1016/j.coviro.2017.04.00528505524
     [Google Scholar]
  23. BenjamanukulS. TraiyanS. YorsaengR. VichaiwattanaP. SudhinarasetN. WanlapakornN. PoovorawanY. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.J. Med. Virol.20229441442144910.1002/jmv.2745834783049
     [Google Scholar]
  24. HotezP.J. BottazziM.E. Whole inactivated virus and protein-based COVID-19 vaccines.Annu. Rev. Med.2022731556410.1146/annurev‑med‑042420‑11321234637324
     [Google Scholar]
  25. HesariT. TahooriF. NazariA. Salehi NajafabadiZ. SamianifardM. FaramarziA. SoleimaniM. Investigation of the effect of PEG detoxification on diphtheria vaccine.Arch. Razi Inst.202277273974536284980
     [Google Scholar]
  26. Tetanus vaccine.Wkly. Epidemiol. Rec.2006812019820816710950
     [Google Scholar]
  27. AroraM. LakshmiR. Vaccines - safety in pregnancy.Best Pract. Res. Clin. Obstet. Gynaecol.202176234010.1016/j.bpobgyn.2021.02.00233773923
     [Google Scholar]
  28. Lago-DeibeF.I. Martín-MiguelM.V. Velicia-PeñasC. Gómez-SerranillosI.R. Fontanillo-FontanilloM. The safety and efficacy of the tetanus vaccine intramuscularly versus subcutaneously in anticoagulated patients: a randomized clinical trial.BMC Fam. Pract.201415114710.1186/1471‑2296‑15‑14725168768
     [Google Scholar]
  29. BullJ.J. NuismerS.L. AntiaR. Recombinant vector vaccine evolution.PLOS Comput. Biol.2019157e100685710.1371/journal.pcbi.100685731323032
     [Google Scholar]
  30. BarouchD.H. PickerL.J. Novel vaccine vectors for HIV-1.Nat. Rev. Microbiol.2014121176577110.1038/nrmicro336025296195
     [Google Scholar]
  31. ConradS.J. LiuJ. Poxviruses as gene therapy vectors: Generating poxviral vectors expressing therapeutic transgenes.Methods Mol. Biol.2019193718920910.1007/978‑1‑4939‑9065‑8_1130706397
     [Google Scholar]
  32. ApoloniaL. The old and the new: Prospects for non-integrating lentiviral vector technology.Viruses20201210110310.3390/v1210110333003492
     [Google Scholar]
  33. GebreM.S. BritoL.A. TostanoskiL.H. EdwardsD.K. CarfiA. BarouchD.H. Novel approaches for vaccine development.Cell202118461589160310.1016/j.cell.2021.02.03033740454
     [Google Scholar]
  34. BasinskiA.J. VarrelmanT.J. SmithsonM.W. MayR.H. RemienC.H. NuismerS.L. Evaluating the promise of recombinant transmissible vaccines.Vaccine201836567568210.1016/j.vaccine.2017.12.03729279283
     [Google Scholar]
  35. McCannN. O’ConnorD. LambeT. PollardA.J. Viral vector vaccines.Curr. Opin. Immunol.20227710221010.1016/j.coi.2022.10221035643023
     [Google Scholar]
  36. HanssonM. NygrenP.A˚. Sta˚hlS. Design and production of recombinant subunit vaccines.Biotechnol. Appl. Biochem.20003229510710.1042/BA2000003411001870
     [Google Scholar]
  37. LundstromK. Self-amplifying RNA viruses as RNA vaccines.Int. J. Mol. Sci.20202114513010.3390/ijms2114513032698494
     [Google Scholar]
  38. HebelC. ThomsenA.R. A survey of mechanisms underlying current and potential COVID-19 vaccines.Acta Pathol. Microbiol. Scand. Suppl.20231312376010.1111/apm.1328436394112
     [Google Scholar]
  39. GiersingB. ShahN. KristensenD. AmorijJ.P. KahnA.L. Gandrup-MarinoK. JarrahianC. ZehrungD. Menozzi-ArnaudM. Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries.Vaccine202139497208721910.1016/j.vaccine.2021.07.09134627624
     [Google Scholar]
  40. Ahmed Saeed AL-JapairaiK. MahmoodS. Hamed AlmurisiS. Reddy VenugopalJ. Rebhi HillesA. AzmanaM. RamanS. Current trends in polymer microneedle for transdermal drug delivery.Int. J. Pharm.202058711967310.1016/j.ijpharm.2020.11967332739388
     [Google Scholar]
  41. YousefH. AlhajjM. SharmaS. Anatomy, skin (integument), epidermisStatPearlsStatPearls: Treasure Island (FL)2023
     [Google Scholar]
  42. QuílezC. de Aranda IzuzquizaG. GarcíaM. LópezV. MonteroA. ValenciaL. VelascoD. Bioprinting for skin.Methods Mol. Biol.2020214021722810.1007/978‑1‑0716‑0520‑2_1432207115
     [Google Scholar]
  43. SorgH. TilkornD.J. HagerS. HauserJ. MirastschijskiU. Skin wound healing: An update on the current knowledge and concepts.Eur. Surg. Res.2017581-2819410.1159/00045491927974711
     [Google Scholar]
  44. UenoH. SchmittN. PaluckaA.K. BanchereauJ. Dendritic cells and humoral immunity in humans.Immunol. Cell Biol.201088437638010.1038/icb.2010.2820309010
     [Google Scholar]
  45. PhataleV. VaipheiK.K. JhaS. PatilD. AgrawalM. AlexanderA. Overcoming skin barriers through advanced transdermal drug delivery approaches.J. Control. Release202235136138010.1016/j.jconrel.2022.09.02536169040
     [Google Scholar]
  46. MishraD.K. DhoteV. MishraP.K. Transdermal immunization: biological framework and translational perspectives.Expert Opin. Drug Deliv.201310218320010.1517/17425247.2013.74666023256860
     [Google Scholar]
  47. EllisonT.J. TalbottG.C. HendersonD.R. VaxiPatch™, a novel vaccination system comprised of subunit antigens, adjuvants and microneedle skin delivery: An application to influenza B/Colorado/06/2017.Vaccine202038436839684810.1016/j.vaccine.2020.07.04032741668
     [Google Scholar]
  48. MogaK.A. BickfordL.R. GeilR.D. DunnS.S. PandyaA.A. WangY. FainJ.H. ArchuletaC.F. O’NeillA.T. DeSimoneJ.M. Rapidly-dissolvable microneedle patches via a highly scalable and reproducible soft lithography approach.Adv. Mater.201325365060506610.1002/adma.20130052623893866
     [Google Scholar]
  49. RodgersA.M. McCruddenM.T.C. Vincente-PerezE.M. DuboisA.V. IngramR.J. LarrañetaE. KissenpfennigA. DonnellyR.F. Design and characterisation of a dissolving microneedle patch for intradermal vaccination with heat-inactivated bacteria: A proof of concept study.Int. J. Pharm.20185491-2879510.1016/j.ijpharm.2018.07.04930048778
     [Google Scholar]
  50. LeoneM. PriesterM.I. RomeijnS. NejadnikM.R. MönkäreJ. O’MahonyC. JiskootW. KerstenG. BouwstraJ.A. Hyaluronan-based dissolving microneedles with high antigen content for intradermal vaccination: Formulation, physicochemical characterization and immunogenicity assessment.Eur. J. Pharm. Biopharm.2019134495910.1016/j.ejpb.2018.11.01330453025
     [Google Scholar]
  51. CaudillC. PerryJ.L. IliadisK. TessemaA.T. LeeB.J. MechamB.S. TianS. DeSimoneJ.M. Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity.Proc. Natl. Acad. Sci. USA202111839e210259511810.1073/pnas.210259511834551974
     [Google Scholar]
  52. WaghuleT. SinghviG. DubeyS.K. PandeyM.M. GuptaG. SinghM. DuaK. Microneedles: A smart approach and increasing potential for transdermal drug delivery system.Biomed. Pharmacother.20191091249125810.1016/j.biopha.2018.10.07830551375
     [Google Scholar]
  53. VučenS.R. VuletaG. CreanA.M. MooreA.C. IgnjatovićN. UskokovićD. Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles.J. Pharm. Pharmacol.201365101451146210.1111/jphp.1211824028612
     [Google Scholar]
  54. S B v JC. MannayeeG. Structural analysis and simulation of solid microneedle array for vaccine delivery applications.Mater. Today Proc.2022653774377910.1016/j.matpr.2022.06.48335855948
     [Google Scholar]
  55. Al-KasasbehR. BradyA.J. CourtenayA.J. LarrañetaE. McCruddenM.T.C. O’KaneD. LiggettS. DonnellyR.F. Evaluation of the clinical impact of repeat application of hydrogel-forming microneedle array patches.Drug Deliv. Transl. Res.202010369070510.1007/s13346‑020‑00727‑232103450
     [Google Scholar]
  56. RzhevskiyA.S. SinghT.R.R. DonnellyR.F. AnissimovY.G. Microneedles as the technique of drug delivery enhancement in diverse organs and tissues.J. Control. Release201827018420210.1016/j.jconrel.2017.11.04829203415
     [Google Scholar]
  57. JungJ.H. JinS.G. Microneedle for transdermal drug delivery: current trends and fabrication.J. Pharm. Investig.202151550351710.1007/s40005‑021‑00512‑433686358
     [Google Scholar]
  58. DeMuthP.C. MinY. HuangB. KramerJ.A. MillerA.D. BarouchD.H. HammondP.T. IrvineD.J. Polymer multilayer tattooing for enhanced DNA vaccination.Nat. Mater.201312436737610.1038/nmat355023353628
     [Google Scholar]
  59. HaoY. LiW. ZhouX. YangF. QianZ. Microneedles-based transdermal drug delivery systems: A review.J. Biomed. Nanotechnol.201713121581159710.1166/jbn.2017.247429490749
     [Google Scholar]
  60. ChoiI.J. ChaH.R. HwangS.J. BaekS.K. LeeJ.M. ChoiS.O. Live vaccinia virus-coated microneedle array patches for smallpox vaccination and stockpiling.Pharmaceutics202113220910.3390/pharmaceutics1302020933546332
     [Google Scholar]
  61. KimY.C. QuanF.S. CompansR.W. KangS.M. PrausnitzM.R. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity.J. Control. Release2010142218719510.1016/j.jconrel.2009.10.01319840825
     [Google Scholar]
  62. MansoorI. EassaH.A. MohammedK.H.A. Abd El-FattahM.A. AbdoM.H. RashadE. EassaH.A. SalehA. AminO.M. NounouM.I. GhoneimO. Microneedle-based vaccine delivery: review of an emerging technology.AAPS PharmSciTech202223410310.1208/s12249‑022‑02250‑835381906
     [Google Scholar]
  63. GuillotA.J. CordeiroA.S. DonnellyR.F. MontesinosM.C. GarriguesT.M. MeleroA. Microneedle-based delivery: an overview of current applications and trends.Pharmaceutics202012656910.3390/pharmaceutics1206056932575392
     [Google Scholar]
  64. KwonK.M. LimS.M. ChoiS. KimD.H. JinH.E. JeeG. HongK.J. KimJ.Y. Microneedles: quick and easy delivery methods of vaccines.Clin. Exp. Vaccine Res.20176215615910.7774/cevr.2017.6.2.15628775980
     [Google Scholar]
  65. Cárcamo-MartínezÁ. MallonB. Domínguez-RoblesJ. VoraL.K. AnjaniQ.K. DonnellyR.F. Hollow microneedles: A perspective in biomedical applications.Int. J. Pharm.202159912045510.1016/j.ijpharm.2021.12045533676993
     [Google Scholar]
  66. van der MaadenK. TrietschS.J. KraanH. VarypatakiE.M. RomeijnS. ZwierR. van der LindenH.J. KerstenG. HankemeierT. JiskootW. BouwstraJ. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats.Pharm. Res.20143171846185410.1007/s11095‑013‑1288‑924469907
     [Google Scholar]
  67. van der MaadenK. HeutsJ. CampsM. PontierM. Terwisscha van ScheltingaA. JiskootW. OssendorpF. BouwstraJ. Hollow microneedle-mediated micro-injections of a liposomal HPV E743–63 synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses.J. Control. Release201826934735410.1016/j.jconrel.2017.11.03529174441
     [Google Scholar]
  68. OgaiN. NonakaI. TodaY. OnoT. MinegishiS. InouA. HachiyaM. FukamizuH. Enhanced immunity in intradermal vaccination by novel hollow microneedles.Skin Res. Technol.201824463063510.1111/srt.1257629707828
     [Google Scholar]
  69. TucakA. SirbubaloM. HindijaL. RahićO. HadžiabdićJ. MuhamedagićK. ČekićA. VranićE. Microneedles: characteristics, materials, production methods and commercial development.Micromachines (Basel)2020111196110.3390/mi1111096133121041
     [Google Scholar]
  70. DuG. HathoutR.M. NasrM. NejadnikM.R. TuJ. KoningR.I. KosterA.J. SlütterB. KrosA. JiskootW. BouwstraJ.A. MönkäreJ. Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles.J. Control. Release201726610911810.1016/j.jconrel.2017.09.02128943194
     [Google Scholar]
  71. AlarconJ.B. HartleyA.W. HarveyN.G. MiksztaJ.A. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines.Clin. Vaccine Immunol.200714437538110.1128/CVI.00387‑0617329444
     [Google Scholar]
  72. CareyJ.B. PearsonF.E. VrdoljakA. McGrathM.G. CreanA.M. WalshP.T. DoodyT. O’MahonyC. HillA.V.S. MooreA.C. Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice.PLoS One201167e2244210.1371/journal.pone.002244221799855
     [Google Scholar]
  73. VrdoljakA. McGrathM.G. CareyJ.B. DraperS.J. HillA.V.S. O’MahonyC. CreanA.M. MooreA.C. Coated microneedle arrays for transcutaneous delivery of live virus vaccines.J. Control. Release20121591344210.1016/j.jconrel.2011.12.02622245683
     [Google Scholar]
  74. EdensC. CollinsM.L. AyersJ. RotaP.A. PrausnitzM.R. Measles vaccination using a microneedle patch.Vaccine201331343403340910.1016/j.vaccine.2012.09.06223044406
     [Google Scholar]
  75. CareyJ.B. VrdoljakA. O’MahonyC. HillA.V.S. DraperS.J. MooreA.C. Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route.Sci. Rep.201441615410.1038/srep0615425142082
     [Google Scholar]
  76. PearsonF.E. O’MahonyC. MooreA.C. HillA.V.S. Induction of CD8+T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine.Vaccine201533283248325510.1016/j.vaccine.2015.03.03925839104
     [Google Scholar]
  77. EdensC. CollinsM.L. GoodsonJ.L. RotaP.A. PrausnitzM.R. A microneedle patch containing measles vaccine is immunogenic in non-human primates.Vaccine201533374712471810.1016/j.vaccine.2015.02.07425770786
     [Google Scholar]
  78. EdensC. Dybdahl-SissokoN.C. WeldonW.C. ObersteM.S. PrausnitzM.R. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque.Vaccine201533374683469010.1016/j.vaccine.2015.01.08925749246
     [Google Scholar]
  79. YangH.W. YeL. GuoX.D. YangC. CompansR.W. PrausnitzM.R. Ebola vaccination using a DNA vaccine coated on PLGA-PLL/γPGA nanoparticles administered using a microneedle patch.Adv. Healthc. Mater.201761160075010.1002/adhm.20160075028075069
     [Google Scholar]
  80. MistilisM.J. JoyceJ.C. EsserE.S. SkountzouI. CompansR.W. BommariusA.S. PrausnitzM.R. Long-term stability of influenza vaccine in a dissolving microneedle patch.Drug Deliv. Transl. Res.20177219520510.1007/s13346‑016‑0282‑226926241
     [Google Scholar]
  81. ZhuW. PewinW. WangC. LuoY. GonzalezG.X. MohanT. PrausnitzM.R. WangB.Z. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.J. Control. Release20172611910.1016/j.jconrel.2017.06.01728642154
     [Google Scholar]
  82. SchipperP. van der MaadenK. GroeneveldV. RuigrokM. RomeijnS. UlemanS. OomensC. KerstenG. JiskootW. BouwstraJ. Diphtheria toxoid and N -trimethyl chitosan layer-by-layer coated pH-sensitive microneedles induce potent immune responses upon dermal vaccination in mice.J. Control. Release2017262283610.1016/j.jconrel.2017.07.01728710002
     [Google Scholar]
  83. ChoiI.J. KangA. AhnM.H. JunH. BaekS.K. ParkJ.H. NaW. ChoiS.O. Insertion-responsive microneedles for rapid intradermal delivery of canine influenza vaccine.J. Control. Release201828646046610.1016/j.jconrel.2018.08.01730102940
     [Google Scholar]
  84. CourtenayA.J. RodgersA.M. McCruddenM.T.C. McCarthyH.O. DonnellyR.F. Novel hydrogel-forming microneedle array for intradermal vaccination in mice using ovalbumin as a model protein antigen.Mol. Pharm.201916111812710.1021/acs.molpharmaceut.8b0089530452868
     [Google Scholar]
  85. BoopathyA.V. MandalA. KulpD.W. MenisS. BennettN.R. WatkinsH.C. WangW. MartinJ.T. ThaiN.T. HeY. SchiefW.R. HammondP.T. IrvineD.J. Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination.Proc. Natl. Acad. Sci. USA201911633164731647810.1073/pnas.190217911631358641
     [Google Scholar]
  86. DonadeiA. KraanH. OphorstO. FlynnO. O’MahonyC. SoemaP.C. MooreA.C. Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies.J. Control. Release2019311-3129610310.1016/j.jconrel.2019.08.03931484041
     [Google Scholar]
  87. PastorY. LarrañetaE. ErhardÁ. QuincocesG. PeñuelasI. IracheJ.M. DonnellyR. GamazoC. Dissolving microneedles for intradermal vaccination against shigellosis.Vaccines (Basel)20197415910.3390/vaccines704015931653077
     [Google Scholar]
  88. KimE. ErdosG. HuangS. KennistonT.W. BalmertS.C. CareyC.D. RajV.S. EpperlyM.W. KlimstraW.B. HaagmansB.L. KorkmazE. FaloL.D.Jr GambottoA. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.EBioMedicine20205510274310.1016/j.ebiom.2020.10274332249203
     [Google Scholar]
  89. YinY. SuW. ZhangJ. HuangW. LiX. MaH. TanM. SongH. CaoG. YuS. YuD. JeongJ.H. ZhaoX. LiH. NieG. WangH. Separable microneedle patch to protect and deliver DNA nanovaccines against COVID-19.ACS Nano2021159143471435910.1021/acsnano.1c0325234472328
     [Google Scholar]
  90. MoonS.S. Richter-RocheM. ReschT.K. WangY. FoytichK.R. WangH. MainouB.A. PewinW. LeeJ. HenryS. McAllisterD.V. JiangB. Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine.NPJ Vaccines2022712610.1038/s41541‑022‑00443‑735228554
     [Google Scholar]
  91. ZhengY. YeR. GongX. YangJ. LiuB. XuY. NieG. XieX. JiangL. Iontophoresis-driven microneedle patch for the active transdermal delivery of vaccine macromolecules.Microsyst. Nanoeng.2023913510.1038/s41378‑023‑00515‑136987502
     [Google Scholar]
  92. ZhangL. XiuX. LiZ. SuR. LiX. MaS. MaF. Coated porous microneedles for effective intradermal immunization with split influenza vaccine.ACS Biomater. Sci. Eng.20239126880689010.1021/acsbiomaterials.3c0121237967566
     [Google Scholar]
  93. KimE. ShinJ. FerrariA. HuangS. AnE. HanD. KhanM.S. KennistonT.W. CassanitiI. BaldantiF. JeongD. GambottoA. Fourth dose of microneedle array patch of SARS-CoV-2 S1 protein subunit vaccine elicits robust long-lasting humoral responses in mice.Int. Immunopharmacol.202412911156910.1016/j.intimp.2024.11156938340419
     [Google Scholar]
  94. WenY. DengS. WangT. GaoM. NanW. TangF. XueQ. JuY. DaiJ. WeiY. XueF. Novel strategy for Poxviridae prevention: Thermostable combined subunit vaccine patch with intense immune response.Antiviral Res.202422810594310.1016/j.antiviral.2024.10594338909959
     [Google Scholar]
  95. OuJ. XingM. LuG. WanC. LiK. JiangW. QianW. LiuY. XuR. ChengA. ZhuM. JuX. GaoY. TianY. NiuZ. Transcutaneous immunization of 1D Rod-Like tobacco-mosaic-virus-based peptide vaccine via tip-loaded dissolving microneedles.Nano Lett.20242442131181312510.1021/acs.nanolett.4c0190039365010
     [Google Scholar]
  96. MooreL.E. VucenS. MooreA.C. Trends in drug- and vaccine-based dissolvable microneedle materials and methods of fabrication.Eur. J. Pharm. Biopharm.2022173547210.1016/j.ejpb.2022.02.01335219862
     [Google Scholar]
  97. ItaK. Dissolving microneedles for transdermal drug delivery: Advances and challenges.Biomed. Pharmacother.2017931116112710.1016/j.biopha.2017.07.01928738520
     [Google Scholar]
  98. PattarabhiranS.P. SajuA. SonawaneK.R. ManimaranR. BhatnagarS. RoyG. KulkarniR.B. VenugantiV.V.K. Dissolvable microneedle-mediated transcutaneous delivery of tetanus toxoid elicits effective immune response.AAPS PharmSciTech201920725710.1208/s12249‑019‑1471‑331332640
     [Google Scholar]
  99. SartawiZ. BlackshieldsC. FaisalW. Dissolving microneedles: Applications and growing therapeutic potential.J. Control. Release202234818620510.1016/j.jconrel.2022.05.04535662577
     [Google Scholar]
  100. ColeG. McCaffreyJ. AliA.A. McBrideJ.W. McCruddenC.M. Vincente-PerezE.M. DonnellyR.F. McCarthyH.O. Dissolving microneedles for DNA vaccination: Improving functionality via polymer characterization and RALA complexation.Hum. Vaccin. Immunother.2017131506210.1080/21645515.2016.124800827846370
     [Google Scholar]
  101. HassanJ. HaighC. AhmedT. UddinM.J. DasD.B. Potential of microneedle systems for COVID-19 vaccination: current trends and challenges.Pharmaceutics2022145106610.3390/pharmaceutics1405106635631652
     [Google Scholar]
  102. KapnickS.M. The nanoparticle-enabled success of COVID-19 mRNA vaccines and the promise of microneedle platforms for pandemic vaccine response.DNA Cell Biol.2022411252910.1089/dna.2021.053834958232
     [Google Scholar]
  103. DonnellyR.F. SinghT.R.R. GarlandM.J. MigalskaK. MajithiyaR. McCruddenC.M. KoleP.L. MahmoodT.M.T. McCarthyH.O. WoolfsonA.D. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery.Adv. Funct. Mater.201222234879489010.1002/adfm.20120086423606824
     [Google Scholar]
  104. ChaiQ. JiaoY. YuX. Hydrogels for biomedical applications: their characteristics and the mechanisms behind them.Gels201731610.3390/gels301000630920503
     [Google Scholar]
  105. TurnerJ.G. WhiteL.R. EstrelaP. LeeseH.S. Hydrogel-forming microneedles: current advancements and future trends.Macromol. Biosci.2021212200030710.1002/mabi.20200030733241641
     [Google Scholar]
  106. WangX. WangN. LiN. ZhenY. WangT. Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systems.Hum. Vaccin. Immunother.20161282075208910.1080/21645515.2016.115836827159879
     [Google Scholar]
  107. YanL. YangY. ZhangW. ChenX. Advanced materials and nanotechnology for drug delivery.Adv. Mater.201426315533554010.1002/adma.20130568324449177
     [Google Scholar]
  108. YuY. LüX. DingF. Influence of poly(L-lactic acid) aligned nanofibers on PC12 differentiation.J. Biomed. Nanotechnol.201511581682710.1166/jbn.2015.197326349394
     [Google Scholar]
  109. McGrathM.G. VucenS. VrdoljakA. KellyA. O’MahonyC. CreanA.M. MooreA. Production of dissolvable microneedles using an atomised spray process: Effect of microneedle composition on skin penetration.Eur. J. Pharm. Biopharm.201486220021110.1016/j.ejpb.2013.04.02323727511
     [Google Scholar]
  110. ChenW. WangC. YanL. HuangL. ZhuX. ChenB. SantH.J. NiuX. ZhuG. YuK.N. RoyV.A.L. GaleB.K. ChenX. Improved polyvinylpyrrolidone microneedle arrays with non-stoichiometric cyclodextrin.J. Mater. Chem. B Mater. Biol. Med.20142121699170510.1039/C3TB21698E32261399
     [Google Scholar]
  111. DangolM. YangH. LiC.G. LahijiS.F. KimS. MaY. JungH. Innovative polymeric system (IPS) for solvent-free lipophilic drug transdermal delivery via dissolving microneedles.J. Control. Release201622311812510.1016/j.jconrel.2015.12.03826732554
     [Google Scholar]
  112. MartinC.J. AllenderC.J. BrainK.R. MorrisseyA. BirchallJ.C. Low temperature fabrication of biodegradable sugar glass microneedles for transdermal drug delivery applications.J. Control. Release201215819310110.1016/j.jconrel.2011.10.02422063007
     [Google Scholar]
  113. DonnellyR.F. SinghT.R.R. WoolfsonA.D. Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety.Drug Deliv.201017418720710.3109/1071754100366779820297904
     [Google Scholar]
  114. SahaI. RaiV.K. Hyaluronic acid based microneedle array: Recent applications in drug delivery and cosmetology.Carbohydr. Polym.202126711816810.1016/j.carbpol.2021.11816834119141
     [Google Scholar]
  115. ZhuJ. TangX. JiaY. HoC.T. HuangQ. Applications and delivery mechanisms of hyaluronic acid used for topical/transdermal delivery – A review.Int. J. Pharm.202057811912710.1016/j.ijpharm.2020.11912732036009
     [Google Scholar]
  116. ShiY. ZhaoJ. LiH. YuM. ZhangW. QinD. QiuK. ChenX. KongM. A Drug-free, hair Follicle cycling regulatable, separable, Antibacterial microneedle patch for hair regeneration therapy.Adv. Healthc. Mater.20221119220090810.1002/adhm.20220090835817085
     [Google Scholar]
  117. MaW. ZhangX. LiuY. FanL. GanJ. LiuW. ZhaoY. SunL. Polydopamine decorated microneedles with Fe-MSC-derived nanovesicles encapsulation for wound healing.Adv. Sci. (Weinh.)2022913210331710.1002/advs.20210331735266637
     [Google Scholar]
  118. ParkJ.H. AllenM.G. PrausnitzM.R. Polymer microneedles for controlled-release drug delivery.Pharm. Res.20062351008101910.1007/s11095‑006‑0028‑916715391
     [Google Scholar]
  119. ChuL.Y. ChoiS.O. PrausnitzM.R. Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery: Bubble and pedestal microneedle designs.J. Pharm. Sci.201099104228423810.1002/jps.2214020737630
     [Google Scholar]
  120. LiJ. ZengM. ShanH. TongC. Microneedle patches as drug and vaccine delivery platform.Curr. Med. Chem.201724222413242228552053
     [Google Scholar]
  121. HongX. WeiL. WuF. WuZ. ChenL. LiuZ. YuanW. Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine.Drug Des. Devel. Ther.2013794595224039404
     [Google Scholar]
  122. OlatunjiO. DasD.B. GarlandM.J. BelaidL. DonnellyR.F. Influence of array interspacing on the force required for successful microneedle skin penetration: theoretical and practical approaches.J. Pharm. Sci.201310241209122110.1002/jps.2343923359221
     [Google Scholar]
  123. UnverdiO.F. CoruhA. Effects of microneedle length and duration of preconditioning on random pattern skin flaps in rats.J. Plast. Reconstr. Aesthet. Surg.20207391758176710.1016/j.bjps.2020.03.02232473851
     [Google Scholar]
  124. YanG. WarnerK.S. ZhangJ. SharmaS. GaleB.K. Evaluation needle length and density of microneedle arrays in the pretreatment of skin for transdermal drug delivery.Int. J. Pharm.20103911-271210.1016/j.ijpharm.2010.02.00720188808
     [Google Scholar]
  125. LiY. HuX. DongZ. ChenY. ZhaoW. WangY. ZhangL. ChenM. WuC. WangQ. Dissolving microneedle arrays with optimized needle geometry for transcutaneous immunization.Eur. J. Pharm. Sci.202015110536110.1016/j.ejps.2020.10536132422374
     [Google Scholar]
  126. MakvandiP. KirkbyM. HuttonA.R.J. ShabaniM. YiuC.K.Y. BaghbantaraghdariZ. JamaledinR. CarlottiM. MazzolaiB. MattoliV. DonnellyR.F. Engineering microneedle patches for improved penetration: analysis, skin models and factors affecting needle insertion.Nano-Micro Lett.20211319310.1007/s40820‑021‑00611‑934138349
     [Google Scholar]
  127. DavisS.P. LandisB.J. AdamsZ.H. AllenM.G. PrausnitzM.R. Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force.J. Biomech.20043781155116310.1016/j.jbiomech.2003.12.01015212920
     [Google Scholar]
  128. DonnellyR.F. GarlandM.J. MorrowD.I.J. MigalskaK. SinghT.R.R. MajithiyaR. WoolfsonA.D. Optical coherence tomography is a valuable tool in the study of the effects of microneedle geometry on skin penetration characteristics and in-skin dissolution.J. Control. Release2010147333334110.1016/j.jconrel.2010.08.00820727929
     [Google Scholar]
  129. van der MaadenK. LuttgeR. VosP.J. BouwstraJ. KerstenG. PloemenI. Microneedle-based drug and vaccine delivery via nanoporous microneedle arrays.Drug Deliv. Transl. Res.20155439740610.1007/s13346‑015‑0238‑y26044672
     [Google Scholar]
  130. GuillotA.J. Martínez-NavarreteM. Zinchuk-MironovaV. MeleroA. Microneedle-assisted transdermal delivery of nanoparticles: Recent insights and prospects.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.2023154e188410.1002/wnan.188437041036
     [Google Scholar]
  131. SeokH. NohJ.Y. LeeD.Y. KimS.J. SongC.S. KimY.C. Effective humoral immune response from a H1N1 DNA vaccine delivered to the skin by microneedles coated with PLGA-based cationic nanoparticles.J. Control. Release2017265667410.1016/j.jconrel.2017.04.02728434892
     [Google Scholar]
  132. ZhuQ. ZarnitsynV.G. YeL. WenZ. GaoY. PanL. SkountzouI. GillH.S. PrausnitzM.R. YangC. CompansR.W. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge.Proc. Natl. Acad. Sci. USA2009106197968797310.1073/pnas.081265210619416832
     [Google Scholar]
  133. KimM.C. LeeJ.W. ChoiH.J. LeeY.N. HwangH.S. LeeJ. KimC. LeeJ.S. MontemagnoC. PrausnitzM.R. KangS.M. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.J. Control. Release201521020821610.1016/j.jconrel.2015.05.27826003039
     [Google Scholar]
  134. YolaiN. SuttiratP. LeelawattanachaiJ. BoonyasiriwatC. ModchangC. Finite element analysis and optimization of microneedle arrays for transdermal vaccine delivery: comparison of coated and dissolving microneedles.Comput. Methods Biomech. Biomed. Engin.202326121379138710.1080/10255842.2022.211657636048187
     [Google Scholar]
  135. ChoiY. LeeG.S. LiS. LeeJ.W. Mixson-HaydenT. WooJ. XiaD. PrausnitzM.R. KamiliS. PurdyM.A. TohmeR.A. Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques.Vaccine202341243663367210.1016/j.vaccine.2023.05.00537179166
     [Google Scholar]
  136. Malek-KhatabiA. TabandehZ. NouriA. MozayanE. SartoriusR. RahimiS. JamaledinR. Long-term vaccine delivery and immunological responses using biodegradable polymer-based carriers.ACS Appl. Bio Mater.20225115015504010.1021/acsabm.2c0063836214209
     [Google Scholar]
  137. TuJ. DuG. Reza NejadnikM. MönkäreJ. van der MaadenK. BomansP.H.H. SommerdijkN.A.J.M. SlütterB. JiskootW. BouwstraJ.A. KrosA. Mesoporous silica nanoparticle-coated microneedle arrays for intradermal antigen delivery.Pharm. Res.20173481693170610.1007/s11095‑017‑2177‑428536970
     [Google Scholar]
  138. WangQ. MaB. LiangQ. ZhuA. WangH. FuL. HanX. ShiX. XiangY. ShangH. ZhangL. Stabilized diverse HIV-1 envelope trimers for vaccine design.Emerg. Microbes Infect.20209177578610.1080/22221751.2020.174509332241249
     [Google Scholar]
  139. RouphaelN.G. PaineM. MosleyR. HenryS. McAllisterD.V. KalluriH. PewinW. FrewP.M. YuT. ThornburgN.J. KabbaniS. LaiL. VassilievaE.V. SkountzouI. CompansR.W. MulliganM.J. PrausnitzM.R. BeckA. EdupugantiS. HeekeS. KelleyC. NesheimW. TIV-MNP 2015 Study Group The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.Lancet20173901009564965810.1016/S0140‑6736(17)30575‑528666680
     [Google Scholar]
  140. Van DammeP. Oosterhuis-KafejaF. Van der WielenM. AlmagorY. SharonO. LevinY. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.Vaccine200927345445910.1016/j.vaccine.2008.10.07719022318
     [Google Scholar]
  141. LevinY. KochbaE. ShukarevG. RuschS. Herrera- TaracenaG. van DammeP. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.Vaccine201634445262527210.1016/j.vaccine.2016.09.00827667332
     [Google Scholar]
  142. AdigwemeI. AkpaluE. YisaM. DonkorS. JarjuL.B. DansoB. MendyA. JeffriesD. NjieA. BruceA. RoyalsM. GoodsonJ.L. PrausnitzM.R. McAllisterD. RotaP.A. HenryS. ClarkeE. Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial=Trials202223177510.1186/s13063‑022‑06493‑536104719
     [Google Scholar]
  143. VescovoP. RettbyN. RamanirakaN. LibermanJ. HartK. CachemailleA. PiveteauL.D. ZanoniR. BartP.A. PantaleoG. Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect™.Vaccine201735141782178810.1016/j.vaccine.2016.09.06928317660
     [Google Scholar]
  144. Leroux-RoelsI. VetsE. FreeseR. SeiberlingM. WeberF. SalamandC. Leroux-RoelsG. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.Vaccine200826516614661910.1016/j.vaccine.2008.09.07818930093
     [Google Scholar]
  145. NormanJ.J. AryaJ.M. McClainM.A. FrewP.M. MeltzerM.I. PrausnitzM.R. Microneedle patches: Usability and acceptability for self-vaccination against influenza.Vaccine201432161856186210.1016/j.vaccine.2014.01.07624530146
     [Google Scholar]
  146. TroyS.B. KouiavskaiaD. SiikJ. KochbaE. BeydounH. MirochnitchenkoO. LevinY. KhardoriN. ChumakovK. MaldonadoY. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV-Infected adults.J. Infect. Dis.2015211121969197610.1093/infdis/jiu84125567841
     [Google Scholar]
  147. ForsterA.H. WithamK. DepelsenaireA.C.I. VeitchM. WellsJ.W. WheatleyA. PryorM. LickliterJ.D. FrancisB. RockmanS. BodleJ. TreasureP. HicklingJ. FernandoG.J.P. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.PLoS Med.2020173e100302410.1371/journal.pmed.100302432181756
     [Google Scholar]
  148. FrewP.M. PaineM.B. RouphaelN. SchamelJ. ChungY. MulliganM.J. PrausnitzM.R. Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity.Vaccine202038457175718110.1016/j.vaccine.2020.07.06432792250
     [Google Scholar]
  149. IwataH. KakitaK. ImafukuK. TakashimaS. HagaN. YamaguchiY. TaguchiK. OyamadaT. Safety and dose-sparing effect of Japanese encephalitis vaccine administered by microneedle patch in uninfected, healthy adults (MNA-J): a randomised, partly blinded, active-controlled, phase 1 trial.Lancet Microbe202232e96e10410.1016/S2666‑5247(21)00269‑X35544051
     [Google Scholar]
  150. MiautonA. AudranR. BessonJ. Maby-El HajjamiH. KarlenM. Warpelin-DecrausazL. SeneL. SchaufelbergerS. FaivreV. FaouziM. HartleyM.A. SpertiniF. GentonB. Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.EBioMedicine20249910492210.1016/j.ebiom.2023.10492238128414
     [Google Scholar]
  151. AdigwemeI. YisaM. OokoM. AkpaluE. BruceA. DonkorS. JarjuL.B. DansoB. MendyA. JeffriesD. Segonds-PichonA. NjieA. CrookeS. El-BadryE. JohnstoneH. RoyalsM. GoodsonJ.L. PrausnitzM.R. McAllisterD.V. RotaP.A. HenryS. ClarkeE. A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.Lancet2024403104391879189210.1016/S0140‑6736(24)00532‑438697170
     [Google Scholar]
  152. GargN. TellierG. ValeN. KlugeJ. PortmanJ.L. MarkowskaA. TusseyL. Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.PLoS One2024196e030345010.1371/journal.pone.030345038843267
     [Google Scholar]
  153. KayembeL.K. FischerL.S. AdhikariB.B. KnappJ.K. KhanE.B. GreeningB.R. PapaniaM. MeltzerM.I. Estimates of potential demand for measles and rubella microarray patches.Vaccines (Basel)2024129108310.3390/vaccines1209108339340113
     [Google Scholar]
  154. SuR. ZhangR. WangY. LiZ. ZhangL. MaS. LiX. MaF. FuH. Simulated skin model for in vitro evaluation of insertion performance of microneedles: design, development, and application verification.Comput. Methods Biomech. Biomed. Engin.202411010.1080/10255842.2024.237262138946229
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673336874241129081141
Loading
Research Progress of Microneedles in Vaccine Delivery
Curr. Med. Chem. 33, 501 (2026); https://doi.org/10.2174/0109298673336874241129081141
/content/journals/cmc/10.2174/0109298673336874241129081141
/content/journals/cmc/10.2174/0109298673336874241129081141
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): epidemics; immunization; Microneedles; MN-based vaccines; transdermal; vaccine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test